Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Cardiology

What is Late Gadolinium Enhancement (LGE) on an HCM MRI?

At a Glance

Late Gadolinium Enhancement (LGE) on a cardiac MRI reveals areas of permanent scar tissue in the heart. For patients with hypertrophic cardiomyopathy, having 15% or more LGE is a major risk factor for dangerous irregular heartbeats and often indicates the need for a protective ICD.

Late Gadolinium Enhancement (LGE) is a technique used during a cardiac MRI (Magnetic Resonance Imaging of the heart) to detect and measure areas of scar tissue in the heart muscle. In people with Hypertrophic Cardiomyopathy (HCM), LGE appears as bright, highlighted spots on the MRI scan, indicating where the heart muscle has been replaced by fibrosis (permanent scar tissue) [1][2].

Why Does Scar Tissue Form in HCM?

Hearing that you have scar tissue in your heart can sound frightening, but it is a common and monitorable part of having HCM. The heart muscle in HCM becomes abnormally thick. Sometimes, this thickening outgrows its blood supply, leading to microvascular ischemia (a lack of adequate blood flow through the smallest blood vessels) [1]. Over time, this lack of blood flow damages the heart muscle cells, causing them to be replaced by fibrous scar tissue [2]. While existing scar tissue is permanent, doctors use medications and regular monitoring to manage the condition and protect your heart.

The Role of LGE in Assessing Risk

A key purpose of measuring LGE—once HCM is diagnosed—is to help evaluate your safety. The overall risk of sudden cardiac events in HCM is actually very low. Measuring the amount of scar tissue helps doctors identify the specific people who could benefit from extra protection [3][4].

Extensive scarring can disrupt the heart’s electrical system, making it easier for dangerous arrhythmias (irregular heartbeats) to start and spread [3][4].

The 15% Threshold

When doctors review an MRI report, they often calculate the percentage of the left ventricle’s mass that is made up of scar tissue. According to the American Heart Association (AHA) and American College of Cardiology (ACC) guidelines, having an LGE extent of 15% or greater is considered “extensive” [5][3].

Research shows that having 15% or more LGE is a major, independent risk factor for dangerous arrhythmias [6][7]. Even if a patient doesn’t have other traditional risk factors—like unexplained fainting or a family history of sudden cardiac events—an LGE of 15% or higher significantly changes how their risk is managed [6][4].

If your LGE is under 15%, it doesn’t mean you are at zero risk, but rather that your doctor will evaluate your LGE alongside other traditional risk factors to make the best care plan for you [5][8]. Also, keep in mind that not all radiology reports list a precise numerical percentage. If your report uses words like “focal,” “mild,” or “extensive,” you can ask your cardiologist to estimate how your scarring aligns with the 15% threshold.

Location Matters

Beyond the total percentage, the location of the scar tissue is also important. In HCM, it is common to have a small amount of LGE at the “junctional points” or “hinge points” (where the right and left ventricles meet). However, scarring that extends outside these standard areas, or involves the inner lining of the heart (subendocardial), can indicate a higher risk and requires closer attention [9][10].

What LGE Means for Your Treatment Plan

The ultimate goal of assessing LGE is prevention. If your LGE is 15% or higher, the AHA/ACC guidelines explicitly state that your doctor may recommend an ICD (Implantable Cardioverter-Defibrillator) [5][3][8]. An ICD is a small device placed in the chest that constantly monitors the heart’s rhythm and can deliver a life-saving shock if a dangerous arrhythmia occurs. By using LGE to identify who needs an ICD, doctors can successfully turn a scary risk into a highly manageable one [4][11].

Common questions in this guide

What does LGE mean on a cardiac MRI?
Late Gadolinium Enhancement (LGE) shows areas of permanent scar tissue, or fibrosis, in the heart muscle. In patients with hypertrophic cardiomyopathy, it highlights where the thickened heart muscle has lost adequate blood supply and become damaged.
Why is a 15% LGE threshold important in HCM?
If your cardiac MRI shows that 15% or more of your left ventricle is made up of scar tissue, it is considered a major risk factor for dangerous abnormal heart rhythms. Doctors use this threshold to help decide if you need extra protection, even if you have no other symptoms.
Does having scar tissue in my heart mean I need an ICD?
Not necessarily, but it is a key factor. If your LGE is 15% or higher, clinical guidelines suggest your doctor may recommend an Implantable Cardioverter-Defibrillator (ICD) to monitor your heart and protect against life-threatening arrhythmias.
Where is the most dangerous place to have heart scar tissue?
While a small amount of scar tissue is common at the hinge points where the right and left ventricles meet, scarring that extends outside these standard areas or involves the inner lining of the heart can indicate a higher risk that needs closer monitoring.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was the total LGE percentage calculated on my most recent cardiac MRI?
  2. 2.Is my scar tissue located in standard areas (like the junctional points), or is it in higher-risk locations?
  3. 3.How does my LGE amount, combined with my other risk factors, impact my need for an ICD?
  4. 4.How often should I have a follow-up cardiac MRI to monitor if the amount of scar tissue is changing?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (11)
  1. 1

    Arrhythmogenic risk of late gadolinium enhancement in patients with hypertrophic cardiomyopathy: Burden and location?

    Montazeri M, Chan RH

    Revista portuguesa de cardiologia 2020; (39(11)):623-624 doi:10.1016/j.repc.2020.10.002.

    PMID: 33162282
  2. 2

    The role of cardiovascular magnetic resonance in sudden death risk stratification in hypertrophic cardiomyopathy.

    Maron MS

    Cardiac electrophysiology clinics 2015; (7(2)):187-93.

    PMID: 26002385
  3. 3

    Updated risk assessments for sudden cardiac death in hypertrophic cardiomyopathy patients with implantable cardioverter-defibrillator.

    Park YM

    The Korean journal of internal medicine 2023; (38(1)):7-15 doi:10.3904/kjim.2022.144.

    PMID: 36353786
  4. 4

    The incremental role of late gadolinium enhancement in risk stratifying high risk patients with hypertrophic cardiomyopathy.

    Ravi SN, O'Shea M, Baqal O, et al.

    American heart journal 2025; (289()):28-37 doi:10.1016/j.ahj.2025.04.030.

    PMID: 40324572
  5. 5

    Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study.

    Rowin EJ, Maron MS, Adler A, et al.

    Heart rhythm 2022; (19(5)):782-789 doi:10.1016/j.hrthm.2021.12.017.

    PMID: 34933112
  6. 6

    Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function.

    Mentias A, Raeisi-Giglou P, Smedira NG, et al.

    Journal of the American College of Cardiology 2018; (72(8)):857-870 doi:10.1016/j.jacc.2018.05.060.

    PMID: 30115224
  7. 7

    The Role of Cardiac MRI in the Diagnosis and Risk Stratification of Hypertrophic Cardiomyopathy.

    Rowin EJ, Maron MS

    Arrhythmia & electrophysiology review 2016; (5(3)):197-202 doi:10.15420/aer.2016:13:3.

    PMID: 28116085
  8. 8

    Role of cardiac magnetic resonance imaging in the management of hypertrophic cardiomyopathy.

    Rowin EJ, Schulz A

    Indian journal of thoracic and cardiovascular surgery 2026; (42(2)):168-180 doi:10.1007/s12055-025-02039-x.

    PMID: 41613491
  9. 9

    The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.

    Klopotowski M, Kukula K, Malek LA, et al.

    Journal of cardiology 2016; (68(1)):49-56.

    PMID: 26363820
  10. 10

    Subendocardial Involvement as an Underrecognized LGE Subtype Related to Adverse Outcomes in Hypertrophic Cardiomyopathy.

    Yang S, Zhao K, Yang K, et al.

    JACC. Cardiovascular imaging 2023; (16(9)):1163-1177 doi:10.1016/j.jcmg.2023.03.011.

    PMID: 37204388
  11. 11

    Assessment of late gadolinium enhancement in hypertrophic cardiomyopathy improves risk stratification based on current guidelines.

    Wang J, Yang S, Ma X, et al.

    European heart journal 2023; (44(45)):4781-4792 doi:10.1093/eurheartj/ehad581.

    PMID: 37795986

This page explains Late Gadolinium Enhancement (LGE) for educational purposes. Always discuss your specific cardiac MRI results, including scar tissue percentage and location, with your cardiologist to understand your individual risk.

Get notified when new evidence is published on Hypertrophic Cardiomyopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.